Xenetic Biosciences, Inc. Balance Sheet
XBIO|13 years of annual SEC 10-K data (FY2012-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 13 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$8M
FY2025
Cash
N/A
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$6M
FY2025
Xenetic Biosciences, Inc. had $8M in total assets and $6M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Receivable | - | - | - | - | - | - | - | - | - | $3.0M | - | - | - |
| Current Assets | $8.0M | $6.6M | $9.6M | $13.7M | $18.7M | $12.4M | $11.1M | $1.2M | $5.9M | $8.3M | $5.3M | $72.9K | $131.1K |
| PP&E (Net) | - | - | - | - | $0 | $0 | $757 | $5.0K | $27.8K | $42.4K | $152.6K | $413.9K | $193.0K |
| Goodwill | - | - | - | - | - | $0 | $3.3M | $3.3M | $3.3M | $3.3M | $3.6M | $3.7M | - |
| Total Assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M | $13.2M | $21.5M | $14.4M | $19.2M | $21.0M | $19.5M | $486.8K | $324.1K |
| Current Liabilities | $968.0K | $894.3K | $809.6K | $1.1M | $1.4M | $936.9K | $1.4M | $1.6M | $1.9M | $1.9M | $3.6M | $456.1K | $204.2K |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | $212.8K |
| Shareholders' Equity | $6.0M | $9.8M | $13.6M | $18.4M | $12.2M | $17.2M | $9.9M | $14.3M | $16.2M | $6.6M | $20.8M | $12.6M | $1.8K |